MAPT and Alzheimer disease: Acyl‐ghrelin has demonstrated promising therapeutic potential for central nervous system (CNS) diseases, including AD, PD, Huntington's disease, and ALS.[7, 32, 33, 34] For example, ghrelin has been shown to disrupt amyloid beta (Aβ) plaques, inhibit tau protein hyperphosphorylation, and mitigate mitochondrial dysfunction, offering potential benefits for AD treatment.[32] Body weight loss, systemic and cellular metabolism impairments, and insulin‐like growth factor‐1 (IGF‐1) reductions are highly associated with faster disease progression and worsening disease outcomes in ALS patients.